tbuckley/cabot-search huggingface dataset:
Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes
Authors: Grace L. Smith, Maria A. Lopez-Olivo, Pragati G. Advani, Matthew S. Ning, Yimin Geng, Sharon H. Giordano, Robert J. Volk
Journal: Journal of the National Comprehensive Cancer Network (2019)

Background: Patients with cancer experience financial toxicity from the costs of treatment, as well as material and psychologic stress related to this burden. A synthesized understanding of predictors and outcomes of the financial burdens associated with cancer care is needed to underpin strategic responses in oncology care. This study systematically reviewed risk factors and outcomes associated with financial burdens related to cancer treatment. Methods: MEDLINE, Embase, PubMed, PsychINFO, and the Cochrane Library were searched from study inception through June 2018, and reference lists were scanned from studies of patient-level predictors and outcomes of financial burdens in US patients with cancer (aged ≥18 years). Two reviewers conducted screening, abstraction, and quality assessment. Variables associated with financial burdens were synthesized. When possible, pooled estimates of associations were calculated using random-effects models. Results: A total of 74 observational studies of financial burdens in 598,751 patients with cancer were identified, among which 49% of patients reported material or psychologic financial burdens (95% CI, 41%–56%). Socioeconomic predictors of worse financial burdens with treatment were lack of health insurance, lower income, unemployment, and younger age at cancer diagnosis. Compared with patients with health insurance, those who were uninsured demonstrated twice the odds of financial burdens (pooled odds ratio [OR], 2.09; 95% CI, 1.33–3.30). Financial burdens were most severe early in cancer treatment, did not differ by disease site, and were associated with worse health-related quality of life (HRQoL) and nearly twice the odds of cancer medication nonadherence (pooled OR, 1.70; 95% CI, 1.13–2.56). Only a single study demonstrated an association with increased mortality. Studies assessing the comparative effectiveness of interventions to mitigate financial burdens in patients with cancer were lacking. Conclusions: Evidence showed that financial burdens are common, disproportionately impacting younger and socioeconomically disadvantaged patients with cancer, across disease sites, and are associated with worse treatment adherence and HRQoL. Available evidence helped identify vulnerable patients needing oncology provider engagement and response, but evidence is critically needed on the effectiveness of interventions designed to mitigate financial burden and impact.
Piwirna-651 Expression Influences Treatment Response and Impacts Survival in Classical Hodgkin Lymphoma Patients through Regulation of ABCC5
Authors: Alfons Navarro, Anna Cordeiro, Anna Gaya, Blanca Gonzalez-Farre, Marina Díaz-Beyá, Dolors Fuster, Carmen Martínez, Jordi Esteve, Antonio Martinez, Mariano Monzó
Journal: Blood (2014)
Non Germinal-Center B Cell Like Diffuse Large B Cell Lymphoma Results From Repeated Activation of IgM B Cells That Resist Class-Switching.
Authors: Philippe Ruminy, Lucile Couronné, Fabrice Jardin, Francoise Parmentier, Vincianne Rainville, Camille Mauger, Jean-Michel Picquenot, Bernard Lenormand, Marie Cornic, Philippe Bertrand, Hervé Tilly, Christian Bastard
Journal: Blood (2009)
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Authors: Graham H Jackson, Faith E Davies, Charlotte Pawlyn, David A Cairns, Alina Striha, Corinne Collett, Anna Waterhouse, John R Jones, Bhuvan Kishore, Mamta Garg, Cathy D Williams, Kamaraj Karunanithi, Jindriska Lindsay, Jamie N Wilson, Matthew W Jenner, Gordon Cook, Martin F Kaiser, Mark T Drayson, Roger G Owen, Nigel H Russell, Walter M Gregory, Gareth J Morgan
Journal: The Lancet Haematology (2019)

Multiple myeloma has been shown to have substantial clonal heterogeneity, suggesting that agents with different mechanisms of action might be required to induce deep responses and improve outcomes. Such agents could be given in combination or in sequence on the basis of previous response. We aimed to assess the clinical value of maximising responses by using therapeutic agents with different modes of action, the use of which is directed by the response to the initial combination therapy. We aimed to assess response-adapted intensification treatment with cyclophosphamide, bortezomib, and dexamethasone (CVD) versus no intensification treatment in patients with newly diagnosed multiple myeloma who had a suboptimal response to initial immunomodulatory triplet treatment which was standard of care in the UK at the time of trial design.
GPRC5D Is a Cell Surface Plasma Cell Marker Whose Expression Is High In Myeloma Cells and Reduced Following Coculture With Osteoclasts
Authors: Sathisha Upparahalli venkateshaiah, Rakesh Bam, Xin Li, Sharmin Khan, Wen Ling, Shelton Randal S, Shmuel Yaccoby
Journal: Blood (2013)
The HCT-Specific Comorbidity Index Fails to Predict Survival After Allogeneic HCT In High Risk AML Patients - A Single Center Experience
Authors: Nicole Birninger, Martin Bornhäuser, Martin Wermke, Stefani Parmentier, Brigitte Mohr, Christoph Röllig, Uwe Platzbecker, Gerhard Ehninger, Johannes Schetelig
Journal: Blood (2010)
Phase I Study Demonstrates Activity and Tolerability of Diphtheria Toxin Interleukin-3 Fusion Protein in Patients with AML and MDS.
Authors: Arthur E. Frankel, E.R. Smith, T.A. George, J.S. Liu, J. Lee, S.K. Park, David A. Rizzieri, Donna E. Hogge
Journal: Blood (2007)
DE-MDCT Predicts Regional Functional Improvement After Reperfused AMI
Authors: Hiroaki Watabe, Akira Sato, Akinori Sugano, Yui Takaiwa, Tomohiko Harunari, Hideaki Aihara, Yuko Fumikura, Tomoya Hoshi, Kentaro Yoshida, Hidetaka Nishina, Kazushi Maruo, Noriyuki Takeyasu, Yuichi Noguchi, Kazutaka Aonuma, Masaki Ieda
Journal: JACC. Cardiovascular imaging (2019)
Government has “moral duty” to act on child obesity, says outgoing chief medical officer
Authors: Gareth Iacobucci
Journal: BMJ (2019)

The UK government is falling short in its efforts to curb childhood obesity and must introduce tougher legislation to protect children’s health, says England’s outgoing chief medical officer, Sally Davies.

In a hard hitting report,1 her last after nine years in the role, she warns that the government is currently “nowhere near” achieving its ambitions to halve childhood obesity by 2030. Government has “a duty as well as a moral responsibility” to uphold children’s rights, which includes being healthy, she says.

Davies said, “The unavoidable fact is that over time, our environment has become very unhealthy without us realising. Our …
Myeloid Neoplasm-Related Gene Abnormalities Differentially Affect FLT3-Ligand Mediated Dendritic Cell Differentiation From Murine Hematopoietic Stem/Progenitor Cells
Authors: Jiro Fujita, Masao Mizuki, Masayasu Otsuka, Sachiko Ezoe, Hirokazu Tanaka, Yusuke Satoh, Kentaro Fukushima, Masahiro Tokunaga, Itaru Matsumura, Yuzuru Kanakura
Journal: Blood (2010)
Clinical and Cytogenetic Characterization of Light Chain Amyloidosis Patients with a Low Amyloidogenic Free Light Chain Count at First Diagnosis
Authors: Tobias Dittrich, Ute Hegenbart, Tilmann Bochtler, Christoph Kimmich, Anna Jauch, Arnt Kristen, Hartmut Goldschmidt, Anthony D. Ho, Stefan Schönland
Journal: Blood (2015)
Specific Chemotherapy and Rituximab In HIV-Infected Patients with Burkitt's Leukemia or Lymphoma. Results of a German-Spanish Study and Analysis of Prognostic Factors
Authors: Josep-Maria Ribera, Christoph Wyen, Mireia Morgades, Christian Hoffmann, Albert Oriol, Gerd Fätkenheuer, Carlos Grande, Markus Mueller, Jordi Esteve, Jan-Christian Wasmuth, Eloy Del Potro, Jan van Lunzen, Salut Brunet, Heribert Knechten, Lourdes Escoda, Angela Hammond, Nuria Alonso, Marcus Hentrich, Ferran Vall-llovera, Christoph Mayr, Montserrat Perez, Jan Thoden, Olga Garcia, Thomas Sternfeld, Timo Wolf, Miguel-Angel Sanz, Dieter Hoelzer
Journal: Blood (2010)
Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis.
Authors: Koichi Takahashi, Hagop M. Kantarjian, Lynne V. Abruzzo, Gautam Borthakur, Guillermo Garcia-Manero, Susan O'Brien, Stefan Faderl, Rajyalakshmi Luthra, William G. Wierda, Alessandra Ferrajoli, Sherry A. Pierce, Farhad Ravandi, Jorge E. Cortes
Journal: Blood (2012)
T Cell Exhaustion and Downregulation of Cytotoxic NK Cells – an Immune Escape Mechanism in Adult Acute Lymphoblastic Leukemia
Authors: Eolia Brissot, Sawa Ito, Kit Lu, Carly Cantilena, B. Douglas Smith, Gabrielle Prince, Hossein Sadrzadeh, Amir T Fathi, Stephen A. Strickland, Nancy F. Hensel, Fariba Chinian, Keyvan Keyvanfar, Minoo Battiwalla, Pawel Muranski, Christopher S. Hourigan, John Barrett
Journal: Blood (2014)
Surgical Resection Alone in Children with Limited Stage Lymphocyte Predominant Hodgkin’s Lymphoma - The Experience of the EuroNet-PHL Group.
Authors: Christine Mauz-Koerholz, Dirk Hasenclever, Stephanie Gorde-Grosjean, Wolfgang Dörffel, Günther Schellong, Ananth Shankar, Georgina Hall, William H. Wallace, Dieter Korholz, Judith Landman-Parker
Journal: Blood (2006)
Unfavorable Outcome of Single-Unit Umbilical Cord Blood Transplantation for Elderly Patients with Myelodysplastic Syndromes.
Authors: Kazunari Aoki, Ken Ishiyama, Hidehiro Itonaga, Takahiro Fukuda, Shuichi Taniguchi, Yasunori Ueda, Noriko Doki, Yasuhiro Sugio, Yasuo Morishima, Tokiko Nagamura, Junji Tanaka, Yoshiko Atsuta, Takayuki Ishikawa, Yasushi Miyazaki
Journal: Blood (2012)
Association of Interleukin-18 Gene Polymorphism with Severity of Chronic Immune Thrombocytopenia (ITP).
Authors: Takayuki Saitoh, Norihiko Moriyama, Tomonori Takani, Takeki Mitsui, Takumi Hoshino, Hiromi Koiso, Akihiko Yokohama, Hiroshi Handa, Masamitsu Karasawa, Hatsue Ogawara, Norifumi Tsukamoto, Hirokazu Murakami
Journal: Blood (2010)
Genetic Profiling Augments Prognostic Value of the EUTOS Long-Term Survival Score for Disease-Specific Mortality in Imatinib-Treated Asian Chronic Myeloid Leukaemia Patients
Authors: Hein Than, Weng Kit Lye, Chiu Hong Seow, Colin Nicholas Sng, John Carson Allen, Charles Chuah
Journal: Blood (2016)
A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, In Older Patients with MDS Refractory to Hypomethylating Agents
Authors: Guillermo Garcia-Manero, Selina Luger, Parmeswaran Venugopal, Lori Maness, Meir Wetzler, Jessica K Altman, David F. Claxton, Stephen Anthony Strickland, James M. Foran, Stuart L Goldberg, Judy Chiao, Hagop M. Kantarjian
Journal: Blood (2010)
Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): A Phase 1 Study
Authors: Anna B. Halpern, Elihu H. Estey, Megan Othus, Kaysey F. Orlowski, Morgan A. Powell, Tara L. Chen, Pamela S. Becker, Bart L. Scott, Paul C. Hendrie, Fabiana Ostronoff, Elizabeth M. Ranker, Mazyar Shadman, Derek L. Stirewalt, Roland B. Walter
Journal: Blood (2014)
Flt3/ITD Enhances Hematopoietic Cell Migration Towards Chemokine CCL2 Independent of Blocking the Negative Feedback Mechanism on Rho-Associated Kinase
Authors: Seiji Fukuda, Chie Onishi, Tomohiro Hirade, Mariko Abe, Takeshi Taketani, Seiji Yamaguchi
Journal: Blood (2014)
Abstract 11476: Role of the Completion Angiogram in Predicting Limb Salvage Following Endovascular Therapy in Patients with Critical Limb Ischemia Presenting with Isolated Below-the-Knee Lesions
Authors: Kei Sato, Osamu Iida, Yoshimitsu Soga, Keisuke Hirano, Daizo Kawasaki, Kenji Suzuki, Yusuke Miyashita, Shinsuke Nanto, Masaaki Uematsu
Journal: Circulation (2011)

Backgrounds: Although endovascular therapy (EVT) has become a first-line therapy for limb salvage (LS) in patients with critical limb ischemia (CLI), LS cannot always be predicted by completion ang...
Evolving Risk of Myelodysplastic Syndromes Among Adolescents and Young Adults Following Radiation Treatment for First Cancers in the United States, 1973 - 2014
Authors: Remco Molenaar, Tomas Radivoyevitch, Hetty E. Carraway, Jaroslaw P. Maciejewski, Mikkael A Sekeres, Sudipto Mukherjee
Journal: Blood (2016)
Cereblon Deficiency Leads to Alteration in c-Myc Regulated Genes, Increased Glucose Uptake and Resistance to JQ1 Bromodomain Inhibition
Authors: Matthew S Beatty, Rebecca S Hesterberg, Ying Han, Eric Padron, Adam W Mailloux, Sean Yoder, Anjali M Rajadhyaksha, Alan F. List, Pearlie K Epling-Burnette
Journal: Blood (2015)
Interim Results From a Phase II Study Of Non-Anthracycline Combination Of Oxaliplatin-Gemcitabine Plus Rituximab (R-GemOx) As First-Line Treatment In Elderly Patients With Diffuse Large B-Cell Lymphoma
Authors: Lei Fan, Li Wang, Ji Xu, Run Zhang, Yuqiong Yang, Dongping Huang, Yunfeng Shen, Min Zhou, Liang Yu, Zhihong Zhang, Wei Xu, Jianyong Li
Journal: Blood (2013)
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
Authors: Jinkuk Kim, Chunguang Hu, Christelle Moufawad El Achkar, Lauren E. Black, Julie Douville, Austin Larson, Mary K. Pendergast, Sara F. Goldkind, Eunjung A. Lee, Ashley Kuniholm, Aubrie Soucy, Jai Vaze, Nandkishore R. Belur, Kristina Fredriksen, Iva Stojkovska, Alla Tsytsykova, Myriam Armant, Renata L. DiDonato, Jaejoon Choi, Laura Cornelissen, Luis M. Pereira, Erika F. Augustine, Casie A. Genetti, Kira Dies, Brenda Barton, Lucinda Williams, Benjamin D. Goodlett, Bobbie L. Riley, Amy Pasternak, Emily R. Berry, Kelly A. Pflock, Stephen Chu, Chantal Reed, Kimberly Tyndall, Pankaj B. Agrawal, Alan H. Beggs, P. Ellen Grant, David K. Urion, Richard O. Snyder, Susan E. Waisbren, Annapurna Poduri, Peter J. Park, Al Patterson, Alessandra Biffi, Joseph R. Mazzulli, Olaf Bodamer, Charles B. Berde, Timothy W. Yu
Journal: New England Journal of Medicine (2019)

Genome sequencing is often pivotal in the diagnosis of rare diseases, but many of these conditions lack specific treatments. We describe how molecular diagnosis of a rare, fatal neurodegenerative condition led to the rational design, testing, and manufacture of milasen, a splice-modulating antisense oligonucleotide drug tailored to a particular patient. Proof-of-concept experiments in cell lines from the patient served as the basis for launching an "N-of-1" study of milasen within 1 year after first contact with the patient. There were no serious adverse events, and treatment was associated with objective reduction in seizures (determined by electroencephalography and parental reporting). This study offers a possible template for the rapid development of patient-customized treatments. (Funded by Mila's Miracle Foundation and others.).
Characterization of Chromosome 20q Deletions In Myeloproliferative Neoplasms Using Microarray Karyotyping and Next-Generation Sequencing
Authors: Roland Jäger, Tiina Berg, Ashot Harutyunyan, Thorsten Klampfl, Francesco Passamonti, Elisa Rumi, Daniela Pietra, Bettina Gisslinger, Damla Olcaydu, Miroslav Penka, Heinz Gisslinger, Mario Cazzola, Robert Kralovics
Journal: Blood (2010)
Dual Targeting With The Selective Histone Deacetylase (HDAC) 6 Inhibitor, ACY-1215, and Bortezomib (BOR) Leads To Marked Disruption Of Protein Degradation Pathways and Apoptosis In Preclinical Models Of Lymphoma
Authors: Jennifer E. Amengual, Paul M Johannet, Xavier Jirau-Serrano, Kelly Zullo, Daniela Hoehn, Govind Bhagat, Maximilian Lombardo, Luigi Scotto, Simon S Jones, Owen A. O'Connor
Journal: Blood (2013)
A Phase I/II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat (LBH589) in Addition to Glucocorticoids in Patients with Acute Graft-Versus-Host Disease
Authors: Lia Perez, Teresa Field, Marcie L Riches, Hugo F Fernandez, Frederick L Locke, Brian C Betts, Joseph Pidala, Erika Elmer, Francisca Beato, Maritza Lienlaf, Pedro Horna, Alejandro Villagra, Claudio Anasetti
Journal: Blood (2014)
Additive Therapeutic Effects of Mesenchymal Stem Cells and IL-37 for Systemic Lupus Erythematosus
Authors: Jianyong Xu, Jieting Chen, Wenlei Li, Wei Lian, Jieyong Huang, Baoyu Lai, Lingyun Li, Zhong Huang
Journal: Journal of the American Society of Nephrology (2019)

Significance Statement Although mesenchymal stem cells might have potential for treating SLE, their immunoregulatory plasticity renders their therapeutic effects unpredictable. The authors genetically modified mesenchymal stem cells to overexpress IL-37—a protein with immunosuppressive activity—and assessed the modified cells’ effects on immune suppression in vitro , as well as the effects of transplanting such cells into a mouse model of SLE. Mice transplanted with IL-37–overexpressing cells displayed improved survival and reduced signs of SLE compared with controls. Expression of IL-37 by mesenchymal stem cells can maintain higher serum levels of IL-37, and these cells had prolonged survival after transplantation, perhaps through IL-37 suppressing the inflammatory microenvironment. The additive therapeutic effects of this approach might offer a way to enhance the stability and effectiveness of mesenchymal stem cells in treating SLE. Background Although mesenchymal stem cells (MSCs) might offer a promising strategy for treating SLE, their immunoregulatory plasticity makes their therapeutic effects unpredictable. Whether overexpressing IL-37, an IL-1 family member with immunosuppressive activity, might enhance the therapeutic effects of these cells for SLE is unknown. Methods We genetically modified MSCs to overexpress IL-37 and assessed their effects on immune suppression in vitro . We also evaluated the effects of such cells versus effects of various controls after transplanting them into MRL/ lpr mice (model of SLE). Results Stem cell characteristics did not appear altered in MSCs overexpressing IL-37. These cells had enhanced immunosuppression in vitro in terms of inhibiting splenocyte proliferation, reducing proinflammatory factors (IL-1 β , TNF- α , IL-17, and IL-6), and suppressing autoantibodies (anti-dsDNA and anti-ANA). Compared with animals receiving control MSCs or IL-37 treatment alone, MRL/ lpr mice transplanted with IL-37–overexpressing cells displayed improved survival and reduced signs of SLE (indicated by urine protein levels, spleen weight, and renal pathologic scores); they also had significantly lower expression of proinflammatory factors, lower total antibody levels in serum and urine, lower autoantibody production, and showed reduced T cell numbers in the serum and kidney. Expression of IL-37 by MSCs can maintain higher serum levels of IL-37, and MSCs had prolonged survival after transplantation, perhaps through IL-37 suppressing the inflammatory microenvironment. Conclusions Mutually reinforcing interaction between MSCs and IL-37 appears to underlie their additive therapeutic effects. Genetic modification to overexpress IL-37 might offer a way to enhance the stability and effectiveness of MSCs in treating SLE.
1p22 and 1p32 Deletions Are Independent Prognosis Factors in Young Patients with Myeloma: The IFM Experience On 1195 Patients
Authors: Benjamin Hebraud, Xavier Leleu, Valerie lauwers-Cances, Murielle Roussel, Gerald Marit, Lionel Karlin, Cyrille Hulin, Catherine Gentil, Francois Guilhot, Laurent Garderet, Thierry Lamy, Sabine Brechignac, Brigitte Pegourie, Jerome Jaubert, Mamoun Dib, Anne-Marie Stoppa, Catherine Sebban, Cecile Fohrer, Jean Fontan, Christophe Fruchart, Didier Bouscary, Bernadette Corront, Gerard Lepeu, Jill Corre, Thierry Facon, Michel Attal, Philippe Moreau, Herve avet-Loiseau
Journal: Blood (2012)
Peripherally Inserted Central Catheters Are a Good Option For Venous Access In The Patients With Hematologic Diseases
Authors: Naoko Takaiwa, Masanori Seki, Naoki Kurita, Yasuhisa Yokoyama, Mamiko Sakata-Yanagimoto, Naoshi Obara, Kazumi Suzukawa, Yuichi Hasegawa, Shigeru Chiba
Journal: Blood (2013)
Philadelphia chromosome‐positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors
Authors: Iman Abou Dalle, Hagop M. Kantarjian, Nicholas J. Short, Marina Konopleva, Nitin Jain, Guillermo Garcia‐Manero, Rebecca Garris, Wei Qiao, Jorge E. Cortes, Susan O'Brien, Partow Kebriaei, Tapan Kadia, Elias Jabbour, Farhad Ravandi
Journal: American Journal of Hematology (2019)

Abstract Despite the advances in the management of Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL) with the introduction of tyrosine kinase inhibitors (TKIs), relapses remain challenging. We reviewed clinical data from adult patients with Ph + ALL who received frontline hyperCVAD chemotherapy with a TKI to determine their outcomes after first relapse. Patients with first morphological relapse after prior complete remission were evaluated for predictors of response and survival. For 57 of 233 (25%) patients, there was morphological relapse after a median of 15.9 months from first remission [range: 5.3‐94]. The choice of salvage treatments was at the discretion of the treating physician. So, 43 (75%) patients received a TKI in combination with their salvage treatment. Second remission was achieved in 41 of 49 (84%) evaluable patients. Median relapse free survival (RFS) was 10.5 months [range, 0.2‐81]. The 1‐year and 2‐year overall survival (OS) were 41% and 20% respectively. On multivariate analysis, only elevated LDH (units/L), the use of first‐generation or no TKI at the time of first relapse and the achievement of a major molecular response (MMR) had a significant effect on OS (HR: 2.82, 95% CI:1.11‐7.16, P = .029; HR = 2.39, 95% CI: 1.07,5.39, P = .034; HR = 0.39, 95% CI: 0.16‐0.94, P = .03, respectively). Whereas, only achievement of MMR was significantly prognostic for RFS with a HR of 0.48 (95% CI: 0.23‐0.98, P = .04). The OS and RFS were comparable between recipients and non‐recipients of allogeneic hematopoietic stem cell transplantation (alloHSCT) at second remission, due to a higher non‐relapse mortality (53%) seen in patients who underwent alloHSCT.
A Biomarker Analysis of Nivolumab in Previously Treated Advanced Gastric Cancer (WJOG10417GTR)
Authors: Hirokazu Shoji, Chie Kudo-Saito, Hiromasa Takaishi, Naoki Takahashi, Tadamichi Denda, Takeshi Kawakami, Kensei Yamaguchi, Junji Furuse, Toshikazu Moriwaki, Toshimi Takano, Ryoichi Sawada, Takahiro Miyamoto, Hiroshi Imazeki, Kazunori Aoki, Kei Muro, Narikazu Boku
Journal: Annals of Oncology (2019)